Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Preferred Dividend Payments (2023 - 2025)

Historic Preferred Dividend Payments for 60 Degrees Pharmaceuticals (SXTPW) over the last 3 years, with Q1 2025 value amounting to $118158.0.

  • 60 Degrees Pharmaceuticals' Preferred Dividend Payments rose 23.5% to $118158.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $483578.0, marking a year-over-year change of. This contributed to the annual value of $483301.0 for FY2024, which is 11897.16% up from last year.
  • Latest data reveals that 60 Degrees Pharmaceuticals reported Preferred Dividend Payments of $118158.0 as of Q1 2025, which was up 23.5% from $130968.0 recorded in Q4 2024.
  • Over the past 5 years, 60 Degrees Pharmaceuticals' Preferred Dividend Payments peaked at $130968.0 during Q4 2024, and registered a low of $101538.0 during Q3 2023.
  • In the last 3 years, 60 Degrees Pharmaceuticals' Preferred Dividend Payments had a median value of $117881.0 in 2024 and averaged $117453.3.
  • Per our database at Business Quant, 60 Degrees Pharmaceuticals' Preferred Dividend Payments soared by 1480.53% in 2024 and then rose by 23.5% in 2025.
  • 60 Degrees Pharmaceuticals' Preferred Dividend Payments (Quarter) stood at $119176.0 in 2023, then rose by 9.89% to $130968.0 in 2024, then dropped by 9.78% to $118158.0 in 2025.
  • Its Preferred Dividend Payments was $118158.0 in Q1 2025, compared to $130968.0 in Q4 2024 and $116571.0 in Q3 2024.